RV failure treatment trial for pulmonary hypertension patients
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pulmonary hypertension (any type) that has led to right heart dysfunction or failure.
- You have symptoms like shortness of breath or fatigue that limit your activity (NYHA class II, III, or IV).
- You have had a blood test and heart ultrasound within the last 3 months showing your right heart is not working properly.
- You have been taking a water pill (loop diuretic) or a specific heart medication (MRA) for at least 4 weeks.
- You have access to an iPhone or Android smartphone or tablet for the study app.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This study tests new “trial tools” and designs for running early research in people with pulmonary hypertension. If you qualify, you may be asked to do extra trial-related procedures to help researchers test the process safely and smoothly.
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
This trial is evaluating a new temporary heart pump called CorVad for people who develop severe right heart failure shortly after heart surgery, a heart attack, or a heart transplant. The pump is designed to help the right side of the heart pump blood when medications are not enough.
This study tests an investigational drug called sotatercept for people who have a specific type of high blood pressure in the lungs that happens along with heart failure with preserved ejection fraction (a stiff heart muscle). The treatment aims to improve your ability to be active and reduce symptoms, and the study will compare it to a placebo to see if it helps.
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.